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Self-emulsifying drug delivery system is mixture of oils, surfactant, cosurfactant, which are emulsified in aqueous media 
under condition of gentle stirring and digestive motility that would be encountered in the gastrointestinal tract. SEDDS is 
one of the approaches to improve the oral bioavailability of the hydrophobic drugs. The liquid SEDDS can be converted 
into solid dosage form without affecting drug release property. Due to its small size the micro/nano emulsified drug can 
easily be absorbed through lymphatic pathways thereby bypassing the hepatic first-pass effect. The main benefit of this 
approach is that pre-dissolving the compound overcomes the initial rate limiting step of particulate dissolution in the 
aqueous environment within the GI tract. Self-emulsification occurs when entropy changes that favor dispersion is 
greater than the energy required to increase the surface area of the dispersion. 
Keywords: SEDDS, oil, surfactant, cosurfactant 
 
INTRODUCTION 
In recent years, the formulation of poor water soluble 
compounds present interesting challenges for formulation 
scientists in the pharmaceutical industry. Up to 45% of 
new chemical entities discovered by the pharmaceutical 
industry are poorly soluble or lipophilic compounds, which 
leads to poor oral bioavailability, high intra- and inter-
subject variability, and lack of dose proportionality. In the 
oral formulation of such compounds, a number of attempts 
- such as decreasing particle size, use of wetting agents, 
co-precipitation, and preparation of solid dispersions have 
been made to modify the dissolution profile and thereby 
improve the absorption rate. Recently, more attention is 
focused on lipid-based formulations to improve the 
bioavailability of poorly water soluble drugs. Among 
many such delivery options, like incorporation of drugs in 
oils, surfactant dispersion, emulsions and liposomes, one 
of the most popular approaches is the self-emulsifying 
drug delivery systems (SEDDSs)1. There are several 
techniques by which the rate & extent of drug absorption 
can be increased as, by increasing the rate or extent of 
dissolution, facilitating the absorption process etc. So, to 
formulate a self emulsifying formulation these approaches 
are generally used. 
 
SEDDS are described as mixtures of oil, surfactant, co-
surfactant and drug. Traditional preparation of SMEDDS 
involves dissolution of drugs in oils and blending with 
suitable solubilizing agents2. It can be used to improve oral 
absorption of highly lipophilic compounds3. SEDDS 
typically produce emulsions with a droplet size range 100 
and 300 nm while SMEDDS are transparent micro 
emulsion with a droplet size of less than 50 nm also the 
concentration of oil in SMEDDS is less than 20 % as 
compared to 40-80% in SEDDS and these are physically 
stable formulation that are easy to manufacture upon mild 
agitation followed by dilution in aqueous media such as GI 
fluids, these systems can form fine oil-in-water (o/w) 
emulsions or microemulsions (SMEDDS)4. They form fine 
oil-in-water emulsions, when introduce into an aqueous 
phase under gentle agitation. Such mixtures are expected 
to self-emulsify quickly in the aqueous media of stomach, 
the digestive motility providing the agitation required for 
emulsification5. Oral absorption of several drugs has been 
reported to be enhanced by SEDDS by one of the several 
mechanisms which include increasing membrane fluidity 
to facilitate transcellular absorption, opening tight junction 
to allow paracellular transport, inhibiting Cytochrome 
P450 (CYP450) enzymes to increase intracellular 
concentration and residence time by surfactants, and 
stimulating lipoprotein/chylomicron production by lipid6. 
 
SEDDS are promising approach for oral delivery of poorly 
water-soluble compounds. It can be achieved by pre-
dissolving the compound in a suitable solvent and filling 
the formulation into capsules. The oral drug delivery of 
hydrophobic drugs may be made possible by SEDDS. The 
Journal of Applied Pharmaceutical Research ISSN No. 2348 – 0335 www.japtronline.com 
 
 
October – December 2014 Volume 2                                        Issue 4  2 
 
main benefit of this approach is that pre-dissolving the 
compound overcomes the initial rate limiting step of 
particulate dissolution in the aqueous environment within 
the GI tract. However, a potential problem is that the drug 
may precipitate out of solution when the formulation 
disperses in the GI tract, particularly if a hydrophilic 
solvent is used (e.g. polyethylene glycol). If the drug can 
be dissolved in a lipid vehicle there is less potential for 
precipitation on dilution in the GI tract, as partitioning 
kinetics will favour the drug remaining in the lipid 
droplets8. There are two types of self‐emulsifying lipid 
formulations (SELFs) systems10. 
-Self‐emulsifying drug delivery systems (SEDDSs). 
-Self‐micro‐emulsifying drug delivery systems 
(SMEDDSs). 
Both SEDDSs and SMEDDSs have different 
characteristics associated with improved drug release 
properties. SEDDS formulations will be having the simple 
binary systems which include lipophilic phase and drug, or 
lipophilic phase, surfactant and drug. And they have the 
droplet size in the range of 200nm-300nm and the 
dispersion has a turbid appearance. And also the 
concentration of oil is 40-80% in SEDDS. The formulation 
of a SMEDDS requires the use of a co‐surfactant to make a 
microemulsion and they are characterized by having 
droplet size below 50nm, and the dispersion has an 
optically clear-to-translucent appearance. The 
concentration of oil in SMEDDS is less than 20 %. The 
potential advantages of these systems (SEDDS) include 
enhanced oral bioavailability enabling reduction in dose, 
more consistent temporal profiles of drug absorption, 
selective targeting of drug(s) toward specific absorption 
window in GIT, protection of drug(s) from the hostile 
environment in gut, control of delivery profiles, reduced 
variability including food effects, protection of sensitive 
drug substances, high drug payloads, liquid or solid dosage 
formulation, physically stable formulations that are 
manufacture easily etc7-11. However these systems also 
suffer from certain disadvantages as traditional dissolution 
method does not work, because these formulations 
potentially dependent on digestion prior to release of the 
drug. This in vitro model needs further development and 
validation before its strength evaluated. Difficulty in 
establishing in vitro - in vivo correlations and hence 
prototype lipid based formulations needs to be developed 
and tested in vivo in a suitable animal model.12 The 
drawback of this system also include chemical instabilities 
of drugs and high surfactant concentrations in formulations 
(approximately 30-60%) which may cause potential 
damage to the GIT. 
 
Composition of SEDDS 
SEDDS are composed of oil, surfactant & their 
formulation depends upon basically three factors which 
include; the nature of oil–surfactant pair, surfactant 
concentration and the temperature at which self 
emulsification occurs. 
Oils  
Oils are most important constituents as these can solubilize 
the lipophilic drugs in a specific amount and can facilitate 
self-emulsifying and increase the fraction of lipophilic 
drug transported via the intestinal lymphatic system & 
increasing absorption from GI tract. Both long chains 
triglycerides and medium-chain triglycerides oils with 
different degree of saturation have been used for the 
formulation of SEDDS. Examples include corn oil, mono, 
di, tri-glycerides, olive oil, oleic acid, sesame oil, beeswax 
etc. 13-16 
Surfactants 
Nonionic surfactants with high hydrophilic–lipophilic 
balance (HLB) values are used in formulation of SEDDS 
(e.g., Tween, Labrasol, Labrafac CM 10, Cremophore, 
etc.)17. The surfactant strength ranges is 30–60% w/w of 
the formulation in order to form a stable SEDDS15. 
Emulsifiers of natural origin are preferred since they are 
considered to be safer than the synthetic surfactants. 
Surfactants have a high HLB and hydrophilicity, which 
assists the immediate formation of o/w droplets and rapid 
spreading of the formulation in the aqueous media. 
Surfactants are amphiphilic in nature and they can dissolve 
or solubilize relatively high amounts of hydrophobic drug 
compounds. It can prevent precipitation of the drug within 
the GI lumen and for prolonged existence of drug 
molecules. 18-22 
Co-solvents 
Relatively high surfactant concentration (usually more 
than 30 % w/w) is needed to produce an effective 
SEDDS23. Cosolvents like diethylene glycol monoethyl 
ether (transcutol), propylene glycol, polyethylene glycol, 
polyoxyethylene, polyethylene glycol ether (Glycofurol)19 
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may be help to dissolve more amounts of hydrophilic 
surfactants or the hydrophobic drug in the lipid base. 
These solvents sometimes play the important role of the 
co-surfactant in the microemulsion systems. 
 
Mechanism of self-emulsification 
According to Reiss, self-emulsification occurs when the 
entropy change that favors dispersion is greater than the 
energy required to increase the surface area of the 
dispersion15. The free energy of the conventional emulsion 
is a direct function of the energy required to create a new 
surface between oil and water phases and can be described 
by the equation: 
DG= S N i p r i 2 S 
Where, DG- The free energy associated with the process 
(ignoring the free energy of mixing), N- number of 
droplets of radius r and s represents the interfacial energy. 
The two phases of emulsion tend to separate with time to 
reduce the interfacial area, subsequently, the emulsion is 
stabilized by emulsifying agents, which form a monolayer 
on the surface of emulsion droplets, and hence reduce the 
interfacial energy, as well as providing a barrier to prevent 
coalescence9. 
 
Formulations of SEDDS  
The following points should be considered in the 
formulations of SEDDS 
1. The solubility of drugs in different oil, surfactant and 
cosolvents. 
2. The selection of oils, surfactant & cosolvent based on 
the drug solubility and preparation of phase diagram. 
3. Mixing of oil, surfactants and co-surfactant at 500C 
with a magnetic stirrer. 
4. Then, dissolve drug in the blank SEDDS with stirring 
to form an isotropic mixture, the addition of drug to 
SEDDS in critical because the drug interferes with self 
emulsifying process to certain extent, which leads to 
changes in optimal oil surfactant ratio, so, design of 
optimal SEDDS require preformulation solubility and 
phase diagram study3. 
5. Cooling to room temperature and equilibrating for 24 
h before use 4.  
Preparation of the solid SEDDS
6
 
Solid SEDDS can be developed mainly by adsorption of 
solid carriers, spray drying, melt extrusion, dry emulsion, 
solid dispersion etc. These solid SEDDS can be converted 
into pellets, tablets and capsule 
1. Solid carriers 
These solid carriers have property to absorb 
liquid/semisolid formulation as self emulsifying system 
(SES). It is a simple procedure, where SES is incorporated 
into a free flowing powder material which has adsorption 
quality23. The mixture is uniformly adsorbed by mixing in 
a blender. This solid mixture is filled into capsule or added 
to more excipient before compression into tablets18. The 
above mixture can then be solidified to powder forms 
using various adsorbents: microporous calcium silicate 
(FloriteTM RE); magnesium aluminum silicate 
(NeusilinTMUS2) and silicon dioxide (SylysiaTM 320). 
2. Spray drying 
In this technique first the prepared formulation containing 
oil, surfactant, drug, solid carrier etc, is sprayed into a 
drying chamber through a nozzle22. The volatile vehicles 
evaporate leaving behind small solid particles. These 
particles are then filled into capsules or compressed into 
tablets. 
3. Melt extrusion 
This formulation technique depends on the property of the 
plastic mass material which can be easily extruded and 
spheronised with pressure. There is no need for addition of 
liquid form of excipient but a constant temperature and 
pressure need to be maintained. 
4. Dry emulsion 
It is mainly o/w emulsion, which is then converted into 
solid form by spray drying/solid carrier/ freeze drying.  
5. Melt extrusion/extrusion spheronization  
Melt extrusion is a solvent‐free process that allows high 
drug loading (65%), and content uniformity. Extrusion is a 
procedure of converting a raw material with plastic 
properties into a product of uniform size, shape and 
density, by forcing it through a die under controlled 
temperature, flow rate, and pressure conditions25. The size 
of the extruder aperture will determined the approximate 
size of the resulting spheroids. The extrusion–
spheronization process is commonly used in the 
pharmaceutical industry to make uniformly sized pellets. 
The extrusion–spheronization process requires first the dry 
mixing of the active ingredients and excipients to achieve a 
homogeneous powder; wet massing with binder followed 
by extrusion into a spaghetti‐like extrudate to get spheroids 
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of uniform size. Then, these are dry sifted to achieve the 
desired size distribution, coating (optional) 7. 
 
Capsule filling with liquid and semisolids self 
emulsifying system
3 
Capsule filling is the simple and most common technology 
for encapsulation of liquid or semi solid SE formulation 
for the oral routes. If it is used for semi solids the heating 
of semisolid excipients to at least at 2080C (above its 
melting points) is done and actice substances are 
incorporated with stirring and this molten mixture is filled 
in capsules and cooled to room temperature.  
Dosage forms for self emulsifying system 
1. Self emulsifying capsule 
After administration of capsules containing conventional 
liquids SE formulations, microemulsion droplets form and 
disperse in the GIT to reach site of absorption15. If 
irreversible phase separation of microemulsion occur an 
improvement of drugs absorption can’t be expected24. This 
problem can be overcome by sodium dodecyl sulfate may 
be added into the SE formulation. The super saturatable 
SEDDS can be designed using small quantity of HPMC to 
prevent precipitation of drug by generating and 
maintaining a super saturatable state in vivo. Liquid SE 
ingredients can be filled into capsules in solid or semi solid 
state obtains by adding solid carriers (absorbents 
polymers). As an example, a solid PEG matrix can be 
chosen3. 
2. Self--emulsifying sustained / controlled release 
tablets 
Combination of lipids and surfactant has presented great 
potential preparing SE tablets. In order to reduce 
significantly the amount of solidifying excipients required 
for transformation of SEDDSs into solid dosage form a 
gelled SEDDS may be prepared20. Colloidal silicon 
dioxide (aerosol 200) may be used as gelling agent for the 
oil based systems, which serves the dual purpose & 
reduced the amount of required solidifying excipients and 
aiding in slowing down of the drug release14. SE tablets are 
of great utility in obviating adverse effect. Inclusion of 
indomethacin (or other hydrophobic NSAID) for example, 
into SE tablets may increase its penetration efficacy 
through GI mucosal membrane, potentially reducing GI 
bleeding. The SES usually is composed of glycerol 
monolaurate and tyloxapol. 
3. Self emulsifying microspheres 
Solid SE sustained release microspheres can be prepared 
using the quasi emulsion solvent diffusion method for the 
spherical crystallization technique26. Zedoary turmeric oil 
release behavior may be controlled by the ratio of 
hydroxypropyl methylcellulose acetate succinate to aerosil 
200 in the formulation29. The plasma concentration time 
profiles can be achieved after oral administration of such 
microspheres into rabbits, with a bioavailability of 133.6% 
with respect to the conventional liquid SEDDS4. 
4. Self emulsifying sustained / controlled release 
pellets 
Pellets, as a multiple dosage form, possess many 
advantages over conventional solid dosages form, such as 
flexibility of manufacture, reducing intra subject and inter 
subject variability of plasma profile and minimizing GI 
irritation without affecting lowering drug bioavailability. 
SE controlled release pellets incorporating drugs in SES 
enhanced their rate of release and then by coating pellet 
with a water insoluble polymer may reduce the rate of drug 
release. Pellets can be prepared by extrusion / 
spheronization and contain to water insoluble model drugs 
(methyl and propyl paraben). SES may contain mono 
diglycerides and polysorbate 803. 
5. Self emulsifying bead 
 Self emulsifying system can be formulated as a solid 
dosage form by using less excipient. Porous polystyrene 
beads (PPB) with complex internal void structures can be 
typically produced by copolymerising styrene and divinyl 
benzene. It is inert and stable over a wide range of pH, 
temperature and humidity. Features, such as bead size and 
pore architecture of PPB, can be found to govern the 
loading efficiency and in vitro drug release from 
SES‐loaded PPB6. 
6. Self emulsifying nanoparticles (SENs) 
Nanoparticle technology can be applied to the formulation 
of self-emulsifying nanoparticle. One of the solvents is an 
injection. In this method, the prepared molten lipid mass 
contains lipid, surfactant and drug. This lipid molten mass 
is injected dropwise into a non-solvent system. This is 
filtered and dried to get nanoparticles. By this method, 100 
nm sized particles with 70-75% drug loading efficiency is 
obtained. The second technique is sonication emulsion 
diffusion evaporation. By this method coloaded 5-
flurouracil and antisense epidermal growth factor receptor 
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(EGFR) plasmids into biodegradable PLGA/carboxy 
methyl-chitosan (CMC) nanoparticles were prepared. The 
mixture of PLGA and CMC had an SE effect, with no 
additional surfactant required. 
7. Self emulsifying solid dispersion 
Solid dispersions could increase the dissolution rate and 
bioavailability of poor water soluble drugs. These 
excipients have the potential to increase further the 
absorption of poor water soluble drugs30. Relative to 
previously used PEG solid dispersions and filled directly 
into hard gelatin capsule in molten state thus obviating the 
former requirement for milling and blending before filling. 
SE excipients like gelucire 44114, labrasol, transcutol and 
TPGS (tocopherol / polyethylene glycol 1000 succinate) 
have been widely used in this field3. 
8. Self emulsifying suppositories  
S‐SEDDS could increase not only GI adsorption but also 
rectal/vaginal adsorption of the drug24. Glycyrrhizin, 
which, by the oral route, achieves therapeutic plasma 
concentrations, can obtain satisfactory therapeutic levels 
for chronic hepatic diseases by either vaginal or rectal SE 
suppositories. These formulations included glycyrrhizin 
and a mixture of a C6–C18 fatty acid glycerol ester and a 
C6–C18 fatty acid macrogol ester7. 
9. Self emulsifying implants 
Research into SE implants has greatly enhanced the utility 
of S‐SEDDS. Example, 1, 3‐bis (2‐chloroethyl)‐1‐ 
nitrosourea (carmustine) a chemotherapeutic agent is use 
to treat malignant brain tumors. However, its effectiveness 
is hindered by its short half‐life. Loomis invented those 
copolymers having a bioresorbable region, a hydrophilic 
region and at least two cross‐linkable functional groups per 
polymer chain. Such copolymers show SE property 
without requirement of an emulsifying agent. These 
copolymers can be used as good sealants for implantable 
prostheses.
 
Table1. Methods of preparation of SEDDS 
Formulation type Composition Characteristics 
Type I Oils without Surfactant Non-dispersible poor solvent capacity except for high 
lipophilic drugs, requires digestion to releases drug 
Type II Oils and water-insoluble 
surfactant 
SEDDS, turbid o/w dispersion (particle size 0.25-2 µm), 
unlike to lose solvent capacity on dispersion, possible loss 
of solvent capacity on digestion 
Type III Oils, water-soluble surfactants 
and co-solvents 
SEDDS/SMEDDS, slightly bluish to clear dispersion, 
possible loss of solvent capacity on dispersion, less easily 
digested, possible loss of solvent capacity on digestion   
Type IV Water-soluble surfactant and co-
solvents (oil free)  
Forms a clear micellar solution on dispersion, likely loss 
of solvent capacity on dispersion, unlikely to be digested  
 
Characterization of SEDDS 
The primary assessment of self-emulsification is visual 
evaluation. The efficiency of self-emulsification could 
be estimated by determining the emulsification time, 
droplet-size distribution and turbidity measurements. 
Visual assessment 
 This may provide important information about the self- 
emulsifying and microemulsifying property of the 
mixture and about the resulting dispersion9. 
Droplet size analysis and particle size measurements 
The droplet size of the emulsions is determined by 
photon correlation spectroscopy, using a Zetasizer able 
to measure sizes between 10 and 4000 nm16. Light 
scattering is monitored at 25°C at a 90° angle, after 
external standardization with spherical polystyrene 
beads. The nanometric size range of the particle is 
retained even after 100 times dilution with water which 
proves the system compatibility with excess water. 
Assessment of self emulsification 
The USP 24 rotating paddle apparatus is used to 
evaluate the efficiency of self-emulsification of different 
mixtures. One gram of mixture is added to 200 ml of 
distilled water with gentle agitation condition provided 
by a rotating paddle at 70 rpm and at a temperature of 
37oC. The process of self emulsification is visually 
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monitored for the rate of emulsification and for the 
appearance of the produced emulsions 4. 
Viscosity determination 
The rheological properties of microemulsion are 
evaluated by Brook Field viscometer if it is o/w types 
and if it is w/o types then high viscous. 
Droplet size analysis 
The droplets size of the emulsion is determined by 
photon correlation spectroscopy using Zeta sizer, 
enables to measure the sizes between 10 and 5000 nm3. 
Thermodynamic stability studies 
The stability of a lipid –based formulation is also 
important for its performance, which can produce 
adverse effect in the form of precipitation of the drug in 
the excipient matrix solution28. In addition, the poor 
physical stability of the formulation can lead to phase 
separation of the excipient, which affects not only 
formulation performance, as well as visual appearance 
of formulation. In addition, incompatibilities between 
the formulations and the gelatin capsules shell can lead 
to brittleness, delayed disintegration, or incomplete 
release of drug. For thermodynamic stability studies 
three main steps, are preformed- 
1. Heating cooling cycle: Six cycles between the 
refrigerator temperature (50C) and 450C with 
storage at each temperature of not less than 48 h is 
studied. Those formulations, which are stable at 
these temperatures, are subjected to centrifugation 
test. 
2. Centrifugation: Passed formulations are centrifuge 
at thaw cycles between 200C and +250C with 
storage at each temperature for not less than 48 h at 
3600 rpm for 20 min. Those formulations that does 
not show any phase separation are taken for the 
freeze thaw stress test. 
3. Freeze thaw cycle: Those formulations that pass 
this test show good stability with no phase 
separation, creaming or cracking. 
 
Dispersibility test 
The efficiency of self-emulsification of oral emulsion is 
assessed by using a standard USP XXII dissolution 
apparatus 2 for dispersibility test. One millilitre of each 
formulation is added in 500 mL of water at 37 ± 1 0C. A 
standard stainless steel dissolution paddle is used with 
rotating speed of 50 rpm to provide gentle agitation. In 
vitro performance of the formulations is visually 
assessed by using the following grading system: 
Grade A: Rapidly forming (within 1 min) emulsion, 
having a clear or bluish appearance. 
Grade B: Rapidly forming, slightly less clear emulsion, 
having a bluish white appearance. 
Grade C: Fine milky emulsion that forming within 2 
min. 
Grade D: Dull, greyish white emulsion having slightly 
oily appearance that is slow to emulsify (longer than 2 
min). 
Grade E: Formulation, exhibiting either poor or 
minimal emulsification with large oil globules present 
on the surface. 
Grade A and B formulations will remain as emulsion 
when dispersed in GIT. While formulation falling in 
Grade C could be recommend for SEDDS formulation8. 
Refractive index and percent transmittance 
Refractive index and percent transmittance prove the 
transparency of formulations. The refractive index of 
the system is measured by refractometer by putting a 
drop of solution on slide and it comparing with water 
(1.222). The percent transmittance of the system is 
measured at particular wavelength using UV 
spectrophotometer against distilled water as blank. If 
refractive index of system is similar to the refractive 
index of water (1.333) and formulation have percent 
transmittance > 98 percent, then formulation have 
transparent nature8. 
In vitro diffusion study 
In vitro diffusion studies are carried out to study the 
drug release behaviors of formulations from liquid 




(1) Improvement of solubility and bioavailability. 
(2) Protection against biodegradations. 
(3) Oral delivery of hydrophobic drugs can be made 
possible by SEDDS. 
(4) SEDDS solved problems associated with the 
delivery of poorly soluble drugs. 
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Examples – Bioavailability enhancement of poorly 
soluble drugs after administrations of SEDDS. 
a. Halofantrine shows higher bioavailability from 
SMEDDS. 
b. Vitamin EBA 3- folds higher from SEDDS27. 
c. Coenzyme Q10 BA 2- folds higher from SEDDS.  
d. Progesterone BA-9 folds higher from SEDDS. 
e. Nimodipine showed improved the in vitro and in 
vivo performance from SMEDDS3. 
 
RECENT APPROACHES IN SELF 
EMULSIFYING DRUG DELIVERY SYSTEMS 
1. Surfactant mixtures resulted in improved 
reproducibility of the plasma profile in terms of 
Cmax and Tmax. 
2. SEDDS of coenzyme Q10 ware prepared and this 
resulted in enhanced bioavailability and reduced 
toxicity. Lipophilic compound WIN 54954 was 
formulated as SEDDS in triglyceride oil/nonionic. 
3. Self-microemulsifying drug delivery system 
(SMEDDS) of Simavastin have been developed to 
enhance its oral bioavailability. This study 
illustrated the potential use of SMEDDS for the 
delivery of hydrophobic compounds10. 
4. A novel SEDDS of PTX (used for the treatment of 
solid tumors) was prepared and was found that 
SEDDS was chemically stable for at least 1 year 
when kept as two part formulation and also the drug 
loading could be increased by approximately 
fivefold. Compared to marketed I.V. formulation, 
the excipient presented a significantly reduced 
cytotoxicity and led to a stable microemulsion15. 
5. An antimalarial drug, Halofantrine, was prepared as 
SEDDS and SMEDDS and resulted in an eight fold 
improvement in absolute oral bioavailability 
relative to previous data of the solid. 
6. Enhanced bioavailability upto 1.88 of silymarin 
was achieved by SMEDDS7. 
7. Using SEDDS, self-nano emulsified drug delivery 
system (SNEDDS) of ubiquinone was prepared and 
the study revealed that SNEDDS overcame the 
drawbacks of the traditional emulsified system, 
such as low solubility and irreversible precipitation 
of the active drug in the vehicle with time1. 
FUTURE PROSPECTS  
In relation to formulation development of poorly soluble 
drugs in the future, there are now techniques being used 
to convert liquid/semi-solid SEDDS and SMEDDS 
formulations into powders and granules, which can then 
be further processed into conventional 'powder-fill' 
capsules or even compressed into tablets. Hot melt 
granulation is a technique for producing granules or 
pellets, and by using a waxy solubilising agent as a 
binding agent, up to 25% solubilising agent can be 
incorporated in a formulation. There is also increasing 
interest in using inert adsorbents, such as the Neusilin 
(Fuji Chemicals) and Zeopharm (Huber) products for 
converting liquids into powders – which can then be 
processed into powder fill capsules or tablets. But to 
obtain solids with suitable processing properties, the 
ratio of SEDDS to solidifying excipients must be very 
high, which seems to be practically non-feasible for 
drugs having limited solubility in oil phase. In this 
regard, it was hypothesized that the amount of 
solidifying excipients required for transformation of 
SEDDS in solid dosage forms will be significantly 
reduced if SEDDS is gelled. Colloidal silicon dioxide 
(Aerosil 200) is selected as a gelling agent for the oil 
based systems, which may serve the dual purpose of 
reducing the amount of solidifying excipients required 
and aiding in slowing drug release. 
 
Table No. 2. Some marketed SEDDS products 
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